James E. Ross

1.7k total citations
40 papers, 1.3k citations indexed

About

James E. Ross is a scholar working on Infectious Diseases, Clinical Biochemistry and Molecular Medicine. According to data from OpenAlex, James E. Ross has authored 40 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 23 papers in Clinical Biochemistry and 10 papers in Molecular Medicine. Recurrent topics in James E. Ross's work include Antimicrobial Resistance in Staphylococcus (27 papers), Bacterial Identification and Susceptibility Testing (23 papers) and Antibiotic Resistance in Bacteria (10 papers). James E. Ross is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (27 papers), Bacterial Identification and Susceptibility Testing (23 papers) and Antibiotic Resistance in Bacteria (10 papers). James E. Ross collaborates with scholars based in United States, Brazil and Japan. James E. Ross's co-authors include Ronald N. Jones, Hélio S. Sader, Rodrigo E. Mendes, Thomas R. Fritsche, Robert K. Flamm, David J. Farrell, Patricia A. Hogan, Mariana Castanheira, Nicole E. Scangarella-Oman and Douglas J. Biedenbach and has published in prestigious journals such as Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.

In The Last Decade

James E. Ross

38 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James E. Ross United States 22 978 621 450 345 211 40 1.3k
Klaudia Kosowska-Shick United States 19 708 0.7× 262 0.4× 380 0.8× 320 0.9× 278 1.3× 35 1.1k
Anne Bolmström United States 19 937 1.0× 430 0.7× 341 0.8× 319 0.9× 579 2.7× 25 1.4k
P E Coudron United States 21 447 0.5× 376 0.6× 243 0.5× 690 2.0× 321 1.5× 38 1.5k
Patricia A. Hogan United States 17 826 0.8× 525 0.8× 330 0.7× 309 0.9× 312 1.5× 24 1.2k
Chris M. Pillar United States 23 623 0.6× 291 0.5× 341 0.8× 573 1.7× 287 1.4× 45 1.4k
Karolina Törneke Sweden 11 374 0.4× 235 0.4× 291 0.6× 375 1.1× 97 0.5× 18 1.1k
R. Vanhoof Belgium 21 491 0.5× 172 0.3× 254 0.6× 561 1.6× 253 1.2× 86 1.4k
An-Jing Kuo Taiwan 21 278 0.3× 293 0.5× 220 0.5× 499 1.4× 389 1.8× 33 1.1k
Jean Duval France 5 991 1.0× 580 0.9× 377 0.8× 491 1.4× 326 1.5× 9 1.6k
Tatiana Bogdanovich United States 17 391 0.4× 179 0.3× 237 0.5× 522 1.5× 275 1.3× 27 1.1k

Countries citing papers authored by James E. Ross

Since Specialization
Citations

This map shows the geographic impact of James E. Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Ross more than expected).

Fields of papers citing papers by James E. Ross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Ross. The network helps show where James E. Ross may publish in the future.

Co-authorship network of co-authors of James E. Ross

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Ross. A scholar is included among the top collaborators of James E. Ross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Ross. James E. Ross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Riedel, Stefan, James E. Ross, David J. Farrell, Robert K. Flamm, & Ronald N. Jones. (2015). Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae. Journal of Clinical Microbiology. 53(12). 3888–3890. 5 indexed citations
3.
Flamm, Robert K., Rodrigo E. Mendes, Patricia A. Hogan, et al.. (2014). In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagnostic Microbiology and Infectious Disease. 81(4). 283–289. 26 indexed citations
4.
Ross, James E., Nicole E. Scangarella-Oman, & Ronald N. Jones. (2013). Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial. Diagnostic Microbiology and Infectious Disease. 75(4). 437–439. 9 indexed citations
5.
Flamm, Robert K., David J. Farrell, Rodrigo E. Mendes, et al.. (2012). LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagnostic Microbiology and Infectious Disease. 74(1). 54–61. 38 indexed citations
6.
Flamm, Robert K., David J. Farrell, Rodrigo E. Mendes, et al.. (2012). ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. Journal of Chemotherapy. 24(6). 328–337. 15 indexed citations
7.
Farrell, David J., Rodrigo E. Mendes, James E. Ross, Hélio S. Sader, & Ronald N. Jones. (2011). LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States. Antimicrobial Agents and Chemotherapy. 55(8). 3684–3690. 69 indexed citations
8.
Ross, James E., David J. Farrell, Rodrigo E. Mendes, Hélio S. Sader, & Ronald N. Jones. (2011). Eight-year (2002-2009) Summary of the Linezolid (Zyvox®Annual Appraisal of potency and Spectrum; ZAAPS) Program in European Countries. Journal of Chemotherapy. 23(2). 71–76. 41 indexed citations
9.
Biedenbach, Douglas J., David J. Farrell, Rodrigo E. Mendes, James E. Ross, & Ronald N. Jones. (2010). Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program. Diagnostic Microbiology and Infectious Disease. 68(4). 459–467. 37 indexed citations
10.
Jones, Ronald N., et al.. (2009). Zyvox® Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagnostic Microbiology and Infectious Disease. 65(4). 404–413. 59 indexed citations
11.
Farrell, David J., Rodrigo E. Mendes, James E. Ross, & Ronald N. Jones. (2009). Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagnostic Microbiology and Infectious Disease. 65(4). 392–403. 71 indexed citations
12.
Jones, Ronald N., Shigeru Kohno, Yasuo Ono, James E. Ross, & Katsunori Yanagihara. (2009). ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagnostic Microbiology and Infectious Disease. 64(2). 191–201. 60 indexed citations
13.
Mendes, Rodrigo E., Ronald N. Jones, Lalitagauri M. Deshpande, James E. Ross, & Hélio S. Sader. (2009). Daptomycin Activity Tested Against Linezolid-Nonsusceptible Gram-Positive Clinical Isolates. Microbial Drug Resistance. 15(4). 245–249. 14 indexed citations
14.
Jones, Ronald N., James E. Ross, Mariana Castanheira, & Rodrigo E. Mendes. (2008). United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagnostic Microbiology and Infectious Disease. 62(4). 416–426. 69 indexed citations
15.
Jones, Ronald N., Thomas R. Fritsche, Hélio S. Sader, & James E. Ross. (2007). LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagnostic Microbiology and Infectious Disease. 59(3). 309–317. 105 indexed citations
16.
Ross, James E., Thomas R. Fritsche, Hélio S. Sader, & Ronald N. Jones. (2007). Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. International Journal of Antimicrobial Agents. 29(3). 295–301. 31 indexed citations
17.
Jones, Ronald N., Thomas R. Fritsche, Hélio S. Sader, & James E. Ross. (2007). Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagnostic Microbiology and Infectious Disease. 59(2). 199–209. 40 indexed citations
18.
Jones, Ronald N., James E. Ross, Thomas R. Fritsche, & Hélio S. Sader. (2005). Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. Journal of Antimicrobial Chemotherapy. 57(2). 279–287. 58 indexed citations
19.
Ross, James E., et al.. (2005). Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagnostic Microbiology and Infectious Disease. 52(1). 53–58. 41 indexed citations
20.
Ross, James E., et al.. (1954). Antibiotic anaphylaxis.. PubMed. 81(1). 9–11. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Klaudia Kosowska-Shick Breakdown of academic impact, for papers by Anne Bolmström Breakdown of academic impact, for papers by P E Coudron Breakdown of academic impact, for papers by Patricia A. Hogan Breakdown of academic impact, for papers by Chris M. Pillar Breakdown of academic impact, for papers by Karolina Törneke Breakdown of academic impact, for papers by R. Vanhoof Breakdown of academic impact, for papers by An-Jing Kuo Breakdown of academic impact, for papers by Jean Duval Breakdown of academic impact, for papers by Tatiana Bogdanovich
Rankless by CCL
2026